Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00193505 | Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refractory Intermediate Grade B-Cell Lymphoma | PHASE2 | COMPLETED | 40 | — | — | Oct 1, 2003 | Aug 1, 2005 | May 3, 2011 | 1 | United States |
| Name | Type | Description |
|---|---|---|
| Ifosfamide | DRUG | - |
| Carboplatin | DRUG | - |
| Etoposide | DRUG | - |
| Rituximab | DRUG | - |
| 90Y Zevalin | DRUG | - |
Inclusion Criteria: To be included in this study, you must meet the following criteria: * Intermediate grade CD20-positive B-cell non-Hodgkin's lymphoma * Persistent lymphoma after one or two previous chemotherapy regimens * Patients should not be considered candidates for high-dose chemotherapy *...